Antony A. Riley - Jul 1, 2023 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role: Chief Financial Officer
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Stock symbol: FBRX
Transactions as of: Jul 1, 2023
Transactions value $: -$3,371
Form type: 4
Date filed: 7/5/2023, 04:06 PM
Previous filing: Apr 4, 2023
Next filing: Aug 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FBRX	Common Stock	Options Exercise	$0	+9.38K	+50.33%	$0.00	28K	Jul 1, 2023	Direct	F1
transaction	FBRX	Common Stock	Tax liability	-$3.37K	-3.24K	-11.57%	$1.04	24.8K	Jul 1, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FBRX	Restricted Stock Units	Options Exercise	$0	-9.38K	-6.67%	$0.00	131K	Jul 1, 2023	Common Stock	9.38K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
F2	On July 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on June 30, 2023 was the settlement price used to calculate the shares withheld.
F3	Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.